中国香港、上海和美国新泽西州: 2024年9月10日，星期二: 和黄医药(中国)有限公司 (简称 "和黄医药" 或 "HUTCHMED") (纳斯达克/伦敦证交所: HCM; 香港交易所: 13) 今日宣布将于在美国圣地亚哥召开的2024年世界肺癌大会 ("WCLC") 以及在西班牙巴塞罗那召开的欧洲肿瘤内科学会 ("ESMO") 2024年年会上公布和黄医药自主研发的化合物的数项研究的最新及更新后的数据。
研究者发起的临床试验
标题：奥希替尼单药或联合赛沃替尼用于一线治疗原发MET 异常、EGFR突变的晚期非小细胞肺癌患者 (CTONG 2008) : 一项II期研究
Osimertinib with or without savolitinib as 1L in de novo MET aberrant, EGFRm advanced NSCLC (CTONG 2008): A Phase II trial
标题：索凡替尼联合小剂量托泊替康用于二线或三线治疗多发远端器官转移的广泛期小细胞肺癌的研究
Study of Surufatinib Combined with Low Dose Topotecan in Second or Third-Line Multiple Distant Organ Metastatic ES-SCLC
标题：索凡替尼联合多西他赛用于治疗驱动基因阴性的复发性晚期非鳞状非小细胞肺癌患者: Ib/II 期研究
Surufatinib Plus Docetaxel in Patients with Relapsed Advanced Driver-Negative Non-Squamous NSCLC: A Phase Ib/II Study
呋喹替尼 (fruquintinib) 的FRESCO-2转移性结直肠癌研究和FRUTIGA胃癌研究的进一步分析、赛沃替尼在胃癌患者中的生物标志物研究，以及由研究者发起的呋喹替尼和索凡替尼 (surufatinib) 研究将于ESMO 2024 年年会上公布。报告详情如下:
公司申办的临床试验：
标题：呋喹替尼治疗伴有或不伴有肝转移的难治性转移性结直肠癌患者的疗效和安全性: FRESCO-2 III期研究的亚组分析
Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase 3 FRESCO-2 trial
标题：呋喹替尼治疗难治性转移性结直肠癌的疗效和安全性: FRESCO-2研究按年龄分组的亚组分析
Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age
标题：呋喹替尼联合紫杉醇治疗既往接受过免疫治疗的患者的疗效: 来自 FRUTIGA 研究的亚组分析
Efficacy of fruquintinib plus paclitaxel (F+PTX) in patients (pts) with prior immunotherapy (prior-IO): subgroup analysis from FRUTIGA study
标题：FRUTIGA 研究中后续抗肿瘤治疗对接受呋喹替尼联合紫杉醇或安慰剂联合紫杉醇的晚期胃或胃食道结合部腺癌患者的影响
Impact of subsequent anti-tumor therapies in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma receiving fruquintinib (F) plus paclitaxel (PTX) or placebo plus PTX in FRUTIGA study
标题：呋喹替尼诱发的高血压与 FRUTIGA (一项呋喹替尼联合紫杉醇治疗经治晚期胃或胃食管结合部腺癌的III 期研究) 临床结果之间的关联
Association between Fruquintinib-induced Hypertension and Clinical Outcomes from FRUTIGA, a Phase 3 Study of Fruquintinib plus Paclitaxel in Previously Treated Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
标题：赛沃替尼治疗MET 扩增的胃食管结合部腺癌或胃癌患者的II 期研究中cfDNA 样本的MET 基因变化分析
Analysis of MET gene alterations in cfDNA samples from a phase II study of savolitinib in patients (pts) with MET-amplified gastroesophageal junction adenocarcinomas or gastric cancer (GEJ/GC)
研究者发起的临床试验：
标题：呋喹替尼联合特瑞普利单抗和短程放疗作为局部晚期直肠癌新辅助治疗的 II 期研究
A phase II clinical study of fruquintinib (Fru) combined with toripalimab (Tor) and short-course radiotherapy (SCRT) as neoadjuvant therapy for locally advanced rectal cancer (LARC)
标题：立体定向消融放疗联合呋喹替尼和替雷利珠单抗治疗转移性结直肠癌: 单臂前瞻性 II 期研究 (RIFLE) 的最新发现
Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)
标题：呋喹替尼联合信迪利单抗和化疗用于一线治疗晚期初治 EGFR 和 ALK 阴性非鳞状非小细胞肺癌: 更新结果
Fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naïve EGFR- and ALK-negative non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results
标题：呋喹替尼联合信迪利单抗和 CAPEOX 用于一线治疗晚期胃/ 胃食管结合部癌: Ib/II 期研究 (FUNCTION)
Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced G/GEJ cancer: A phase 1b/2 clinical trial (FUNCTION)
标题：呋喹替尼联合白蛋白结合型紫杉醇和吉西他滨 (AG方案) 用于一线治疗伴有肝转移的胰腺导管腺癌: 一项开放标签、单臂、单中心 II 期研究
Fruquintinib combined with nab-paclitaxel and gemcitabine (AG) as the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with liver metastases: An open-label, single-arm, single-center phase II clinical study
标题：呋喹替尼用于一线或二线治疗不可切除的转移性软组织肉瘤的 II 期研究
A phase II study of Fruquintinib in the 1L or 2L treatment of unresectable metastatic soft tissue sarcoma
标题：索凡替尼联合抗PD-1/PD-L1抗体用于二线治疗或单药用于三线治疗晚期肝细胞癌: 一项单臂、开放标签、多中心II期研究
Surufatinib combined with anti-PD-1/PD-L1 antibody in the second line or monotherapy in third line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study
标题：索凡替尼联合经动脉栓塞对比索凡替尼单药治疗伴有肝转移的神经内分泌瘤的最新结果: 一项前瞻性、随机、对照试验
Updated results of Surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: a prospective, randomized, controlled trial
标题：索凡替尼联合特瑞普利单抗加培美曲塞和铂类用于治疗晚期非鳞状非小细胞肺癌患者: 一项单中心II 期研究的更新结果
Surufatinib plus toripalimab combined with pemetrexed (A), and platinum (P) in patients (pts) with advanced non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results of a single-center, phase II trial
标题：索凡替尼联合吉西他滨用于治疗蒽环类化疗失败或安罗替尼单药治疗后疾病进展的软组织肉瘤患者: 一项多中心 II 期研究
Surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients failed with anthracyclines chemotherapy or monotherapy post-anlotinib progression: a multi-center, phase II trial
